Garrido-Castro AC, Kim SE, Li T, Desrosiers J, et al. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. Ann Oncol 2026 Jun 20:S0923-7534(26)00960-9. doi: 10.1016/j.annonc.2026.
PMID: 42323161